Molecular Subtype
Triple-Negative Breast Carcinoma
CI-CAN-00008567TNBCExplore in graph →
417 active trials3 approved drugs8 evidence items
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00008567TNBCExplore in graph →
Clinical trials
950 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (168)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04191135 | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) | terminated | Phase 2 | 462 | Merck Sharp & Dohme LLCINDUSTRY | 15 | Sep 14, 2026 | clinicaltrials |
| NCT05756166 | Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 5 | Roswell Park Cancer InstituteOTHER |
| 1 |
| Aug 31, 2026 |
| clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | terminated | Phase 1 / Phase 2 | 14 | TCR2 TherapeuticsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04331067 | Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer | terminated | Phase 1 / Phase 2 | 15 | Washington University School of MedicineOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT04216472 | Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations | terminated | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer | terminated | Phase 2 | 77 | Regeneron PharmaceuticalsINDUSTRY | 2 | Jun 9, 2026 | clinicaltrials |
| NCT06171789 | PRO1107 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | GenmabINDUSTRY | 2 | Jun 1, 2026 | clinicaltrials |
| NCT04789668 | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | terminated | Phase 1 / Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03801369 | AMTEC IIT: Phase 2 Multiarm Study in TNBC | terminated | Phase 2 | 24 | Gordon Mills, MD, PhDOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT04095689 | Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer(INTEGRAL) | terminated | Phase 2 | 8 | The Methodist Hospital Research InstituteOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | terminated | Phase 1 / Phase 2 | 73 | Ocellaris Pharma, Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04770272 | Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy(neoMono) | terminated | Phase 2 | 442 | Palleos Healthcare GmbHINDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04986852 | Olinvacimab With Pembrolizumab in Patients With mTNBC | terminated | Phase 2 | 19 | PharmAbcineINDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT03225547 | Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer | terminated | Phase 2 | 24 | University of ChicagoOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 31 | TransgeneINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT03979508 | Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer | terminated | Phase 2 | 26 | Mayo ClinicOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT04504916 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) | terminated | Phase 2 | 102 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 2 | Nov 10, 2025 | clinicaltrials |
| NCT04958785 | Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer(ELEVATE TNBC) | terminated | Phase 2 | 92 | Gilead SciencesINDUSTRY | 6 | Nov 4, 2025 | clinicaltrials |
| NCT03901469 | A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer(TNBC) | terminated | Phase 2 | 115 | Zenith EpigeneticsINDUSTRY | 4 | Oct 7, 2025 | clinicaltrials |
| NCT03838367 | Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC | terminated | Phase 1 / Phase 2 | 10 | CytoDyn, Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 143 | MacroGenicsINDUSTRY | 4 | Jul 31, 2025 | clinicaltrials |
| NCT05300958 | Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer | terminated | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | HutchmedINDUSTRY | 1 | Jul 14, 2025 | clinicaltrials |
| NCT03094169 | AVID100 in Advanced Epithelial Carcinomas | terminated | Phase 1 / Phase 2 | 49 | Formation BiologicsINDUSTRY | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06067061 | "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer(neoBREASTIM) | terminated | Phase 1 / Phase 2 | 2 | Institut CurieOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT04849364 | Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer(PERSEVERE) | terminated | Phase 2 | 52 | Bryan Schneider, MDOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | Numab Therapeutics AGINDUSTRY | 3 | May 23, 2025 | clinicaltrials |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | terminated | Phase 1 / Phase 2 | 222 | Kymab LimitedINDUSTRY | 6 | Apr 2, 2025 | clinicaltrials |
| NCT05336721 | A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC | terminated | Phase 2 | 9 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Mar 24, 2025 | clinicaltrials |
| NCT05113966 | Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer | terminated | Phase 2 | 30 | G1 Therapeutics, Inc.INDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | terminated | Phase 2 | 315 | Novartis PharmaceuticalsINDUSTRY | 15 | Oct 9, 2024 | clinicaltrials |
| NCT03872388 | Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy | terminated | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT04123704 | Sitravatinib in Metastatic Breast Cancer | terminated | Phase 2 | 3 | Xiang ZhangOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT03387085 | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. | terminated | Phase 1 / Phase 2 | 9 | ImmunityBio, Inc.INDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT04927884 | A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies | terminated | Phase 1 / Phase 2 | 3 | ImmunityBio, Inc.INDUSTRY | 1 | Jun 12, 2024 | clinicaltrials |
| NCT04461600 | A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer(TENACITY) | terminated | Phase 2 | 18 | Ayala Pharmaceuticals, Inc,INDUSTRY | 5 | Feb 12, 2024 | clinicaltrials |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | terminated | Phase 1 / Phase 2 | 25 | pharmaand GmbHINDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT04690855 | A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer(TARA) | terminated | Phase 2 | 1 | Mylin A. Torres, MDOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT04441099 | NBE-002 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 12 | NBE-Therapeutics AGINDUSTRY | 1 | Sep 7, 2023 | clinicaltrials |
| NCT04639245 | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 3 | Aug 1, 2023 | clinicaltrials |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 4 | Jul 25, 2023 | clinicaltrials |
| NCT04489940 | Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer | terminated | Phase 2 | 11 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 6 | Apr 10, 2023 | clinicaltrials |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies(REVEAL) | terminated | Phase 1 / Phase 2 | 64 | Nektar TherapeuticsINDUSTRY | 1 | Mar 8, 2023 | clinicaltrials |
| NCT02124902 | Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity | terminated | Phase 2 | 148 | Washington University School of MedicineOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT02457910 | Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 30 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT03674242 | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2) | terminated | Phase 2 / Phase 3 | 27 | ERYtech PharmaINDUSTRY | 3 | Aug 1, 2022 | clinicaltrials |
| NCT02720185 | Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR | terminated | Phase 2 | 5 | University of Wisconsin, MadisonOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT01234532 | Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery(0927GCC) | terminated | Phase 2 | 5 | University of Maryland, BaltimoreOTHER | 1 | May 3, 2022 | clinicaltrials |
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials